A Systematic Review and Meta-Analysis of the Effectiveness of Adherence Therapy and Its Treatment Duration in Patients with Schizophrenia Spectrum Disorders

Abstract

Background Adherence therapy (AT) is an intervention for improving medication adherence of people with schizophrenia spectrum disorders, but no systematic reviews have yet summarized the effectiveness and minimum treatment duration of AT. We here aimed to systematically examine the effectiveness of AT in improving outcomes versus treatment as usual (TAU) and its minimum effective duration for people diagnosed with schizophrenia spectrum disorders. Patients and Methods Eligible randomized controlled trials were identified from four databases (Web of Science, PubMed, CINAHL and Cochrane Library) for the period 1 January 2006 to 1 January 2023. Of 1087 retrieved candidate studies, five studies with a total of 726 participants met the inclusion criteria. The search terms consisted of adherence therapy, compliance therapy, schizophrenia, schizoaffective disorder, schizophrenic disorder, medication adherence, and medication compliance (combined with OR and AND). Two investigators independently selected studies, extracted data, and conducted bias risk assessments. Random-effects models were used to analyze the pooled data. Results Meta-analysis of the five selected studies showed that AT had a significantly greater positive effects than TAU on psychiatric symptoms, but no significant effects on adherence behaviors and attitudes. Conclusion The AT had limited effects in terms of improving the attitudes and behaviors of people with schizophrenia spectrum disorders with respect to medication adherence, but did improve patients’ psychiatric symptoms. The therapy should be performed by trained staff for maximum benefit, and the recommended duration of the intervention is 12 hours.

Structural Equation Modelling to Identify Psychometric Determinants of Medication Adherence in a Survey of Kidney Dialysis Patients

“…59 To our knowledge, there have been no studies exploring medication knowledge as a sole intervention, with most addressing medication knowledge in multi-faceted interventions, some of which have been successful. [60][61][62][63] The contribution of improved medication knowledge to such success is moot. We have found only one other structural analysis of medication knowledge in this literature, although that study did not include assessments from the BMQ, and therefore, is not directly comparable.…”

Schizophrenia - Time to Commit to Policy Change

“…Anti-inflammatory medications seem to effectively target the underlying inflammatory states present in a subgroup of patients with schizophrenia. 39,[148][149][150]157 Using such agents as add-on therapies has shown promise in first episode psychosis and in patients with predominant immune alterations. 148,152,153 Future trials will aim to assess the consistency of these promising initial findings.…”

“…A systematic review of randomised trials assessing the value of additional adherence therapy compared with treatment as usual found a significant effect of controlling psychiatric symptoms but only a minimal effect on medication adherence. 157 Combining educational and motivational strategies shows potential benefits for adherence. 158 Tailored multidisciplinary approaches are most likely to succeed, 159 considering the strengths and weaknesses of various methods.…”

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction

“…Antipsychotic drugs are the mainstay of its treatment, however, about 26.5% to 58.8% of people with SZ are non-adherent to their antipsychotic medication regimen [10,11]. Some factors linked with nonadherence include not being well informed about medications and the negative perceptions of taking medications [6,[11][12][13][14]. Poor adherence, in turn, is associated with a higher risk of symptom recurrence, rehospitalization, poor quality of life, and healthcare costs [15,16].…”